Medtech industry raises concern over US FDA guidance on benefit-risk assessment
This article was originally published in Clinica
Executive Summary
Medtech industry stakeholders have expressed concern over a guidance document the US Food and Drug Administration has drafted to explain the factors it considers when making benefit-risk determinations during medical device pre-market reviews.